Profile
| Metric | Value |
|---|---|
| Full Name | Phathom Pharmaceuticals, Inc. |
| Ticker | NASDAQ: PHAT |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | phathompharma.com |
| Employees | 427 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $15.83 | |
| Price, 1D Change | +0.76% | |
| Market Cap | $1B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.42 | |
| Revenue | $55M | |
| Revenue, 1Y Change | +8,001.47% | |
| EPS | -$5.29 | |
| EPS, 1Y Change | -34.64% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$5.29 | |
| EPS Estimate | -$2.34 | |
| EPS Est. Change | +55.70% | |
| Revenue | $55.25M | |
| Revenue Estimate | $173.67M | |
| Revenue Est. Change | +214.33% | |
| Current Price | $15.83 | |
| Price Target | - | $24.00 |
| Price Tgt. Change | - | +51.61% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$3.72 | -$3.93 | -5.66% | |
| -$4.70 | -$5.29 | -12.54% | |
| -$2.34 | N/A | +55.70% | |
| -$0.10 | N/A | +98.11% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $400.00K | $682.00K | +70.50% | |
| $51.25M | $55.25M | +7.82% | |
| $173.67M | N/A | +214.33% | |
| $317.65M | N/A | +474.92% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +104.52% | |
| Price, 3Y | +105.32% | |
| Market Cap, 1Y | +112.34% | |
| Market Cap, 3Y | +252.22% | |
| Revenue, 1Y | +8,001.47% | |
| Revenue, 3Y | +100.00% | |
| EPS, 1Y | -34.64% | |
| EPS, 3Y | -36.10% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $15.83 | |
| SMA 200 | $10.00 | |
| SMA 200 vs Price | -36.81% | |
| SMA 50 | $14.92 | |
| SMA 50 vs Price | -5.75% | |
| Beta | 1.42 | |
| ATR | $0.82 | |
| 14-Day RSI | 50.01 | |
| 10-Day Volatility | 57.86% | |
| 1-Year Volatility | 128.92% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $55.25M | |
| EPS | -$5.29 | |
| Gross Profit | $47.28M | |
| Gross Margin | 85.57% | |
| Operating Profit | -$277.47M | |
| Operating Margin | -502.18% | |
| Net Income | -$334.33M | |
| Net Margin | -605.09% | |
| EBITDA | -$261.52M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | -2.19 | |
| 4.20 | ||
| 4.16 | ||
| -3.64 | ||
| 3 | ||
| -4.87 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| 7.65 | ||
| -2.67 | ||
| -7.40 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | -$253.58M | |
| $297.26M | ||
| $378.47M | ||
| $360.13M | ||
| $632.05M | ||
| $85.73M | ||
| Total Debt | $554.95M | |
| $501.00K | ||
| $10.51M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $332.72M | ||
| $324.75M | ||
| $7.97M | ||
| $290.66M | ||
| $795.00K | ||
| $72.01M | ||
| $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$266.77M | ||
| -$135.00K | ||
| $182.77M | ||
| Capex | $135.00K | |
| -$266.91M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Barclays | ||
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| Craig-Hallum | → | |
| Needham | → | |
| HC Wainwright & Co. | → | |
| Guggenheim | → | |
| Goldman Sachs | → | |
| Craig-Hallum | → | |
| Needham | → |
Analyst sentiment
Institutional ownership
Screeners with PHAT
Data Sources & References
- PHAT Official Website www.phathompharma.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1783183/000119312525257390/0001193125-25-257390-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1783183/000095017025034183/0000950170-25-034183-index.htm
- PHAT Profile on Yahoo Finance finance.yahoo.com/quote/PHAT
- PHAT Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/phat
FAQ
What is the ticker symbol for Phathom Pharmaceuticals, Inc.?
The ticker symbol for Phathom Pharmaceuticals, Inc. is NASDAQ:PHAT
Does Phathom Pharmaceuticals, Inc. pay dividends?
No, Phathom Pharmaceuticals, Inc. does not pay dividends
What sector is Phathom Pharmaceuticals, Inc. in?
Phathom Pharmaceuticals, Inc. is in the Healthcare sector
What industry is Phathom Pharmaceuticals, Inc. in?
Phathom Pharmaceuticals, Inc. is in the Biotechnology industry
What country is Phathom Pharmaceuticals, Inc. based in?
Phathom Pharmaceuticals, Inc. is headquartered in United States
When did Phathom Pharmaceuticals, Inc. go public?
Phathom Pharmaceuticals, Inc. initial public offering (IPO) was on October 25, 2019
Is Phathom Pharmaceuticals, Inc. in the S&P 500?
No, Phathom Pharmaceuticals, Inc. is not included in the S&P 500 index
Is Phathom Pharmaceuticals, Inc. in the NASDAQ 100?
No, Phathom Pharmaceuticals, Inc. is not included in the NASDAQ 100 index
Is Phathom Pharmaceuticals, Inc. in the Dow Jones?
No, Phathom Pharmaceuticals, Inc. is not included in the Dow Jones index
When was Phathom Pharmaceuticals, Inc. last earnings report?
Phathom Pharmaceuticals, Inc.'s most recent earnings report was on October 30, 2025
When does Phathom Pharmaceuticals, Inc. report earnings?
The next expected earnings date for Phathom Pharmaceuticals, Inc. is March 5, 2026